Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Inclusion Criteria: Confirmed diagnosis of primary immune deficiency and medical records available for retrospective review for at least 3 months prior to entry into the trial Signed an informed consent written informed consent prior to initiation of any study related procedures Receiving regular infusions of IGIV at a fixed interval and dosage (in the range of 200-600 mg/kg given every 3-4 weeks) for at least three months prior to entry into the trial. Patients who are currently receiving less than 400 mg/kg are eligible for this trial and will be at the time of study enrollment be treated at 400 mg/kg Exclusion Criteria: History or suspicion of significant allergic reaction to intravenous immune globulin, and/or blood products Documented history of selective IgA deficiency (serum level <5.0 mg/dL) and known antibodies to IgA Isolated IgG subclass deficiency with a normal total serum IgG level Other conditions which may interfere with the trial, include the patients demeanor or mental ability to follow instruction. Pretreatment with anti-pyretics or anti-histamines Congestive heart failure (New York Heart Association stage greater than Class II) Renal insufficiency (creatinine >2.5 mg/dL) Conditions whose symptoms and effects could alter protein catabolism and/or IgG utilization (e.g. protein-losing enteropathies, nephrotic syndrome) Pretreatment routinely required to control/ameliorate IGIV infusion-related adverse events (AEs) Any patient who requires IGIV dosing more frequently than every 3 weeks to maintain adequate trough levels Women of child bearing potential who do not practice adequate contraception (i.e. chemical or mechanical methods) and pregnant or lactating females